Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation
- Qi Shen†1,
- Sichu Liu†1,
- Yu Chen1, 2,
- Lijian Yang1,
- Shaohua Chen1,
- Xiuli Wu1,
- Bo Li1,
- Yuhong Lu3,
- Kanger Zhu3 and
- Yangqiu Li1, 2Email author
© Shen et al.; licensee BioMed Central Ltd. 2013
Received: 17 August 2013
Accepted: 31 August 2013
Published: 3 September 2013
Despite the success of imatinib and other tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) remains largely incurable, and a number of CML patients die due to Abl mutation-related drug resistance and blast crisis. The aim of this study was to evaluate proliferation inhibition and apoptosis induction by down-regulating PPP2R5C gene expression in the imatinib-sensitive and imatinib-resistant CML cell lines K562, K562R (imatinib resistant without an Abl gene mutation), 32D-Bcr-Abl WT (imatinib-sensitive murine CML cell line with a wild type Abl gene) and 32D-Bcr-Abl T315I (imatinib resistant with a T315I Abl gene mutation) and primary cells from CML patients by RNA interference. PPP2R5C siRNAs numbered 799 and 991 were obtained by chemosynthesis. Non-silencing siRNA scrambled control (SC)-treated, mock-transfected, and untreated cells were used as controls. The PPP2R5C mRNA and protein expression levels in treated CML cells were analyzed by quantitative real-time PCR and Western blotting, and in vitro cell proliferation was assayed with the cell counting kit-8 method. The morphology and percentage of apoptosis were revealed by Hoechst 33258 staining and flow cytometry (FCM). The results demonstrated that both siRNAs had the best silencing results after nucleofection in all four cell lines and primary cells. A reduction in PPP2R5C mRNA and protein levels was observed in the treated cells. The proliferation rate of the PPP2R5C-siRNA-treated CML cell lines was significantly decreased at 72 h, and apoptosis was significantly increased. Significantly higher proliferation inhibition and apoptosis induction were found in K562R cells treated with PPP2R5C-siRNA799 than K562 cells. In conclusion, the suppression of PPP2R5C by RNA interference could inhibit proliferation and effectively induce apoptosis in CML cells that were either imatinib sensitive or resistant. Down-regulating PPP2R5C gene expression might be considered as a new therapeutic target strategy for CML, particularly for imatinib-resistant CML.
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder that occurs because of t(9;22)(q34;q11) translocations. CML prognoses markedly improved after the introduction of Abl tyrosine kinase inhibitors (TKIs). Since its approval in 2001 for frontline CML management, imatinib has proven to be effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve an optimal response. Most patients with CML treated with imatinib will relapse if treatment is withdrawn, and numerous CML patients die due to Abl mutation-related drug resistance and blast crisis. These circumstances have led researchers to develop a new generation of TKIs. Although second-generation TKIs, such as AMN107, appear to improve the treatment of CML, TKI resistance and relapse also frequently occur in patients. de novo and secondary TKI resistance are significant problems for CML [1–5]. Therefore, how to treat patients with CML who are resistant to Bcr-Abl tyrosine kinase inhibitors is an important and urgent issue for clinical hematology.
Moreover, TKIs have significant off-target inhibitory effects on multiple kinases. TKIs, through the off-target PPP2R5Cinhibition of kinases important for B-cell signaling, reduce memory B-cell frequency and induce significant impairment of B-cell responses in CML . TKIs also impair T cell function e.g., imatinib impairs CD8+ T cells specifically directed against leukemia-associated antigen function .
Further advances in the treatment of CML may require the development of novel agents such as siRNAs that target specific CMLs or specific immunotherapies without significant toxicity that may have cooperative effects with TKIs [8, 9]. siRNAs targeting the Bcr-Abl and multidrug-resistance (MDR-1) genes were used in an anti-CML study and demonstrated that a breakpoint-specific short-interfering RNA (siRNA) was capable of decreasing Bcr-Abl protein expression and antagonizing Bcr-Abl-induced biochemical activities [10–12].
Synthetic small interfering RNAs (siRNAs) are promising gene-targeting agents that have shown great potential, particularly for development as specific anti-leukemia treatment [13, 14]. A combination of c-raf and bcl-2 siRNAs induced apoptosis in HL-60, U937, and THP cell lines and increased chemosensitivity to etoposide and daunorubicin .
Recently, we were the first to show that a higher PPP2R5C expression level is found in peripheral blood mononuclear cells from chronic phase CML patients, and PPP2R5C expression is significantly decreased in patients who achieved CR . PPP2R5C is a regulatory B subunit of protein phosphatase 2A (PP2A), which is one of the main serine-threonine phosphatases in mammalian cells, and it maintains cell homeostasis by counteracting most of the kinase-driven intracellular signaling pathways . The PPP2R5C gene encodes five different spliced variants including B56γ1, B56γ2, B56γ3, B56γ5, B56γ6, and B56γ4, which is only found in mice. The locus for the functional PPP2R5C gene is at 14q32.2, and a nonfunctional B56γ1 pseudogene for PPP2R5C is located at 3p21.3 [16–18]. PPP2R5C plays a crucial role in cell proliferation, differentiation, and transformation based on its induction of the dephosphorylation of p53 at various residues . It has been reported that the dynamic nuclear distribution of the B56γ3 regulatory subunit controls nuclear PP2A activity and may be responsible for the tumor-suppressive function of PP2A . Recently, alterations in the PPP2R5C expression pattern that are associated with malignant transformation have been characterized in lung cancer, and the PPP2R5C mutation F395C disrupts the B56γ–p53 interaction .
To confirm the role of PPP2R5C in the proliferation of CML, we analyzed the effect of down-regulating PPP2R5C gene expression in imatinib-sensitive and imatinib-resistant chronic myeloid leukemia (CML) cell lines and primary cells from CML patients by RNA interference and confirmed the proliferation inhibition and apoptosis induction of PPP2R5C in CML cells.
Imatinib-sensitive K562 cells (Institutes for Biological Sciences Cell Resource Center, Chinese Academy of Sciences, Shanghai, China) carrying 210 kDa wild-type Bcr-Abl were grown in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco-BRL, Grand Island, NY, USA) with 10% fetal calf serum (FCS) (Sijiqing Co., Hangzhou, China) and maintained in a humidified incubator at 37°C and 5% CO2. Imatinib-resistant K562R cells (provided by Prof. Jingxuan Pan, Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China) carrying 210 kDa wild-type Bcr-Abl were routinely maintained in the same medium including 1 μM imatinib. 32D-Bcr-Abl WT, an imatinib-sensitive murine CML cell line carrying a wild type Abl gene, and 32D-Bcr-Abl T315I, an imatinib-resistant CML cell line carrying a T315I mutation in Bcr-Abl (provided by Prof. Lin Qiu, Harbin Institute of Hematolgy & Oncology, Harbin, China), were established and maintained in RPMI 1640 medium with 10% FCS as previously described . In addition, PBMCs from two patients with newly diagnosed, untreated chronic phase CML (case 1: female, 18 years old, PB white blood cell number (WBC): 108.6 × 109/L, PB blast + promyelocyts 10%, case 2: female, 30 years old, WBC: 208.53 × 109/L, PB blast + promyelocytes 3%), which were obtained with consent (the procedures were conducted according to the guidelines of the Medical Ethics committee of the health bureau of Guangdong Province of China), were grown in RPMI 1640 with 15% FCS. All experiments were performed using cells in the exponential growth phase.
siRNA design and synthesis
The siRNAs PPP2R5C-siRNA799 (Chinese patent number: ZL 201110340411.1) and PPP2R5C-siRNA991 (Chinese patent number: ZL 201110337837.1), which target domains in the sixth and between the eighth and ninth exons in the PPP2R5C gene (ACCESSION NM_178587), respectively, and a non-silencing siRNA scrambled control (SC) were designed with online software (http://www.invitrogen.com) and synthesized by Invitrogen (Carlsbad, CA, USA) . An Alexa Red Oligo (Invitrogen) was used to measure transfection efficiency.
Cells were collected by centrifugation and resuspended at 2.5 × 106 cells/100 μl for the CML cell lines and primary CML cells in the appropriate Nucleofector™ kit V solution (Amaxa Biosystems, Cologne, Germany) [23–26]. Malignant CML cells were nucleofected with 3 μg of the PPP2R5C siRNAs or a non-silencing scrambled control (SC) siRNA using the T-003 program of the Nucleofection Device II (Amaxa Biosystems). Mock-transfected cells nucleofected without siRNA were used as a negative control. After nucleofection, the cells were immediately mixed with 500 μl of pre-warmed culture medium and transferred into culture plates. The treated cells were incubated at 37°C for 3 days for cell proliferation, apoptosis and microarray analyses. Three independent experiments for the cell lines were performed every 24 h.
RNA isolation, reverse transcription, real-time qRT–PCR
Total RNA was isolated from different samples (CML cell lines and primary CML cells) using TRIzol (Invitrogen). cDNA for qRT-PCR was synthesized using the Superscript II RNaseH Reverse Transcriptase Kit (Invitrogen). The expression level of PPP2R5C and the β2-MG reference gene was determined by SYBR Green I real-time PCR. PCR was performed as previously described . The sequences of the primers used in qRT-PCR are as follows: PPP2R5C: 5′-GTAATAAAGCGGGCAGCAGG-3′ (forward) and 5′-CAAAGTCAAAGAGGACGCAACA-3′ (reverse) and β 2 M: 5′-CAGCAAGGAC TGGTCTTTCTAT-3′ (forward) and 5′-GCGGCATCTTCAAACCTC-3′ (reverse) .
A total of 2 × 106 K562 and K562R cells were collected 72 h after nucleofection, and proteins were extracted using a RIPA total protein lysate kit (Shennengbocai, Shanghai, China). Protein quantification was performed according to conventional methods. Protein samples (30 μg) were added to SDS loading buffer, heated at 100°C for 5 min, and then electrophoresed in 10% SDS-polyacrylamide gels at 100 V for 30 min followed by 120 V for 50 min (Bio-Rad). The separated proteins were transferred onto nitrocellulose membranes (Invitrogen) using a tank system (Bio-Rad). The membranes were blocked with 3% blocking reagent for 2 h and then incubated with polyclonal rabbit anti-human PPP2R5C antibody (1:200; Sigma, USA) or mouse anti-actin antibody (1:1000; Lianke, Hangzhou, China) followed by incubation with goat anti-rabbit or donkey anti-mouse IgG antibodies, respectively (Jackson ImmunoResarch, USA; Lianke, Hangzhou, China). Immunoreactive proteins were visualized by chemiluminescence (Lianke, Hangzhou, China), and images were obtained with a Vilber Lourmat system (UVI, UK). The expression level of PPP2R5C was calculated with image quantitation analysis software using β-actin as a reference gene [25, 26].
Cell proliferation assays
The proliferation of CML cell lines and primary CML cells was indirectly assayed using the CCK-8 kit (Dojindo, Japan), which stains living cells. After transfection, approximately 5 × 104 cells in 100 μL, including control cells, were incubated in triplicate in 96-well plates. At 24, 48, and 72 h, the CCK-8 reagent (10 μL) was added to each well, and the cells were incubated at 37°C for 6 h. The optical density at 450 nm was measured using an automatic microplate reader (Synergy4; Bio-Tek, Winooski, VT, USA) .
At 72 h post-transfection, 5 × 104 of the CML cell lines and primary CML cells were fixed, washed twice with PBS, and stained with Hoechst 33258 staining solution according to the manufacturer’s instructions (Beyotime, Haimen, China). Changes in the nuclei of cells after Hoechst 33258 staining were observed with a confocal laser-scanning microscope (LSM 510 META DuoScan; Carl Zeiss, Germany). The cell lines (5 × 105) were collected 48 and 72 h after transfection and then prepared with FITC-labeled anti-Annexin-V (BD Pharmingen, San Diego, CA, USA) and propidium iodide (Kaiji, Nanjing, China) according to the manufacturers’ protocol and measured by flow cytometry (Beckman Coulter, Fullerton, CA, USA). The results were analyzed using Windows MDI 2.9 software .
Statistical analyses were performed with paired t-tests and one-way ANOVA using SPSS 11.5 statistical software. Kruskal-Wallis analysis was used to analyze the PPP2R5C mRNA levels in different samples. Differences were considered statistically significant at p < 0.05.
PPP2R5C-specific siRNAs suppress PPP2R5C expression in CML cells
To determine the suppression of PPP2R5C expression in CML cells after siRNA treatment, PPP2R5C mRNA expression was analyzed by qRT–PCR 24, 48, and 72 h after nucleofection, while the suppression of PPP2R5C protein expression in K562 and K562R cells was analyzed by immunoblotting 72 h after nucleofection. PPP2R5C-siRNA799 and PPP2R5C-siRNA991 were measured from 24 to 72 h post-transfection. The PPP2R5C mRNA level in K562 cells was 7.00 ± 0.83 and 6.44 ± 0.87% at 24 h with PPP2R5C-siRNA799 and PPP2R5C-siRNA991 transfection, respectively, while the SC level was 26.11 ± 2.69% (Figure1). The PPP2R5C mRNA level in K562R cells was 5.06 ± 1.47 and 6.23 ± 1.19% at 24 h with PPP2R5C-siRNA799 and PPP2R5C-siRNA991 transfection, respectively, while the SC level was 21.37 ± 1.17% (Figure 2). Similar inhibition results were found for the protein levels. The PPP2R5C protein expression level was reduced by 55.26 and 52.58% in PPP2R5C-siRNA799- and PPP2R5C-siRNA991-treated K562 cells, respectively, compared with the control level at 72 h (Figure 1), while the reduction in treated K562R cells was 53.81 and 50.21%, respectively (Figure 2).
We also analyzed the suppression effect of both siRNAs in the murine CML cell lines 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I. The PPP2R5C mRNA level in 32D-Bcr-Abl WT cells was 5.71 ± 2.45 and 8.88 ± 1.39% at 24 h with PPP2R5C-siRNA799 and PPP2R5C-siRNA991, respectively, while the SC level was 20.25 ± 1.37% (Additional file 1: Figure S1). The PPP2R5C mRNA level in 32D-Bcr-Abl T315I cells was 3.14 ± 2.04 and 3.18 ± 1.13% at 24 h with PPP2R5C-siRNA799 and PPP2R5C-siRNA991, respectively, while the SC level was 12.04 ± 1.11% (Additional file 2: Figure S2). A reduction in the PPP2R5C mRNA levels was also observed at 48-72 h. The PPP2R5C mRNA level in primary leukemic CML cells was decreased 4.71 and 6.09% at 24 h with PPP2R5C-siRNA799 and PPP2R5C-siRNA991, respectively, compared with the SC (14.01%). A reduction in the PPP2R5C mRNA level was also observed at 48-72 h (Additional file 3: Figure S3). Although the 32D-Bcr-Abl WT and 32D-Bcr-Abl T315I cells are originally from a mouse, the PPP2R5C siRNAs target the same sequences in these cells due to homology of the mouse PPP2R5C and that of humans according to data from GenBank.
PPP2R5C suppression inhibits proliferation and induces apoptosis in CML cells
Targeted therapies are directed at unique molecular signatures of cancer cells to produce greater efficacy with less toxicity. The development and use of such therapeutics allow us to practice personalized medicine and improve cancer care . Imatinib is the first successful molecular drug specifically targeting the Abl gene and has proven to be effective in achieving high remission rates and improving CML prognosis. Because TKI resistance and relapse frequently occur in patients, new targeted drugs that can specifically inhibit TKI-resistant CML urgently need to be developed. RNAi represents a new alternative for CML treatment that overcomes the difficulties of current drug treatments such as acquired resistance. The therapeutic targeting of Bcr-Abl transcripts by siRNA was demonstrated in imatinib-resistant CML cells [10, 28].
PPP2R5C plays a crucial role in cell proliferation, differentiation, and transformation based on its induction of the dephosphorylation of p53 at various residues  and may be responsible for the tumor-suppressive function of PP2A . To confirm the role of PPP2R5C down-regulation on the inhibition of CML cells, particularly TKI-resistant CML cells, we used two PPP2R5C siRNAs that target different exon sequences to analyze their effect on the inhibition of proliferation and apoptosis induction in CML cells. Moreover, to investigate the PPP2R5C siRNA effects in imatinib-resistant CML cells, we selected two pairs of CML cell lines, including the imatinib-sensitive cell lines K562 and 32D-Bcr-Abl WT and the imatinib-resistant cell lines K565R, which lacks an Abl mutation, and 32D-Bcr-Abl T315I, which has an T315I Abl mutation, to compare the different changes induced by PPP2R5C siRNA.
In general, RNAi effects are detected between 24 and 72 h after siRNA transfection. We demonstrated that the siRNAs effectively silenced PPP2R5C post-transcriptionally, and the control siRNA had no obvious influence 72 h after nucleofection. These results were confirmed at the RNA and protein levels. siRNAs targeting different exon domains had different efficacies for PPP2R5C gene silencing and subsequent biological consequences. Both PPP2R5C siRNAs demonstrated significant effects on the knockdown of PPP2R5C expression in CML cell lines, and PPP2R5C-siRNA799, which targets exon six, demonstrated robust knockdown of PPP2R5C expression in K562R cells at all time points.
There are reports that siRNAs targeting Bcr-abl increased sensitivity to imatinib in Bcr-Abl-overexpressing cells and cells expressing the imatinib-resistant Bcr-Abl kinase domain mutations H396P and Y253F [10, 28]. There are no reports regarding the effects of the suppression of PPP2R5C on changing cell biological functions. Our previous study first demonstrated that the suppression of PPP2R5C by RNAi effectively inhibited the proliferation of the Molt-4 and Jurkat cell lines; however, the suppression of PPP2R5C by RNAi could not significantly induce apoptosis in Molt-4 and Jurkat T cells . In contrast, the PPP2R5C siRNAs not only inhibited cell proliferation but also induced apoptosis in imatinib-sensitive and imatinib-resistant CML cell lines. These results indicated that down-regulating PPP2R5C could significantly inhibit the proliferation of CML cells, and the underlying mechanism might be different between CML and T-ALL cells. More importantly, we found a significantly higher inhibition effect in K562R cells treated with PPP2R5C-siRNA799, and the inhibition effect in 32D-Bcr-Abl T315I cells, which have a T315I Abl mutation, was similar to that of 32D-Bcr-Abl WT cells. Such effects are particularly important for the targeted therapy of imatinib-resistant CML cells that either lack an Abl mutation and have primary and imatinib-induced resistance or those with an Abl T315I mutation, which resist new-generation TKIs. Therefore, it is interesting to analyze the molecular mechanism of PPP2R5C siRNA-mediated cell proliferation suppression in different leukemia cells. It has been reported that TKI-resistant, Philadelphia chromosome-positive cell lines without an Abl mutation are unique because they dephosphorylate ERK1/2 and STAT5 after imatinib treatment, while PI3K/AKT1/mTOR activity remains unaffected. The inhibition of AKT1 leads to apoptosis in imatinib-resistant cell lines. Therefore, these Ph + cell lines show a form of imatinib-resistance attributable to the constitutive activation of the PI3K/AKT1 pathway . Whether down-regulating PPP2R5C contributes similar effects to the inhibition of PI3K/AKT1/mTOR signaling requires further investigation. We also found that PPP2R5C siRNA could inhibit the proliferation of primary CML cells in limited experiments, and this effect should be further explored using a larger patient cohort.
Moreover, whether PPP2R5C siRNAs could potentiate the efficacy of TKIs in imatinib-resistant cells is worthy of further investigation. One study has shown a synergistic effect between AMN107 and arsenic trioxide (ATO) or Bcr-Abl-siRNA in the K562R imatinib-resistant cells or those with an H396P abl mutation, indicating that the combination of AMN107 and ATO or siRNA may represent a new strategy for the treatment of imatinib-resistant CML patients [10, 29].
In conclusion, our findings provide evidence for the effect of proliferation inhibition and apoptosis induction in CML cells by PPP2R5C knockdown, and such effects may particularly benefit developing a strategy including a combination of targeted therapy using TKIs for resistant cells. A successful clinical trial demonstrated that the in vivo application of targeted nonvirally delivered synthetic Bcr-abl siRNA in a female patient with recurrent CML that was imatinib resistant (Y253F mutation) and chemotherapy after an allogeneic hematopoietic stem cell transplantation could silence the expression of the Bcr-Abl gene . These data imply that siRNA may be suitable for development as a specific anti-leukemia treatment. However, a recent study demonstrated that the phosphatase activity of PP2A is suppressed in chronic myeloid leukemia and other malignancies characterized by aberrant oncogenic kinase activity, and preclinical studies show that the pharmacological restoration of PP2A tumor-suppressor activity by PP2A-activating drugs (e.g., FTY720) effectively antagonizes cancer development and progression . These findings appear to be contrary to our results, and further characterization of the function of the different regulatory B subunits of PP2A and a discussion of the different effects on the different PP2A target subunits is needed.
This study was supported by grants from National Natural Science Foundation of China (30871091), a collaborate grant for HK-Macao-TW of the Ministry of Science and Technology (2012DFH30060), the Guangdong Science & Technology Project (2012B050600023), Science and Technology Innovation Key Project of Guangdong Higher Education Institutes (kjcxzd1013) and Key Discipline Construction Foundation of Jinan University.
- Jabbour E, Cortes J, Kantarjian H: Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol. 2009, 4: 3-10. 10.1007/s11523-008-0100-y.View ArticlePubMedGoogle Scholar
- Okabe S, Tauchi T, Tanaka Y, Ohyashiki K: Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line. J Hematol Oncol. 2011, 4: 32-10.1186/1756-8722-4-32.PubMed CentralView ArticlePubMedGoogle Scholar
- Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG: BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011, 4: 6-10.1186/1756-8722-4-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Bhamidipati PK, Kantarjian H, Cortes J, Cornelison AM, Jabbour E: Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2013, 4: 103-117. 10.1177/2040620712468289.PubMed CentralView ArticlePubMedGoogle Scholar
- Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP: Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013, 122: 515-522. 10.1182/blood-2013-02-483750.View ArticlePubMedGoogle Scholar
- de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, Mielke S, Bazeos A, Stringaris K, Ali S, Milojkovic D, Foroni L, Chaidos A, Cooper N, Gabriel I, Apperley J, Belsey S, Flanagan RJ, Goldman J, Shpall EJ, Kelleher P, Marin D, Rezvani K: Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood. 2013, 122: 227-238. 10.1182/blood-2012-11-465039.View ArticlePubMedGoogle Scholar
- Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Döhner H, Bunjes D, Schmitt M: Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunol Immunother. 2007, 56: 849-861. 10.1007/s00262-006-0232-9.View ArticlePubMedGoogle Scholar
- Valencia-Serna J, Gul-Uludağ H, Mahdipoor P, Jiang X, Uludağ H: Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation. J Control Release. 2013, 10.1016/j.jconrel.2013.05.014 [Epub ahead of print]Google Scholar
- Li Y, Lin C, Schmidt CA: New insights into antigen specific immunotherapy for chronic myeloid leukemia. Cancer Cell Int. 2012, 12: 52-10.1186/1475-2867-12-52.PubMed CentralView ArticlePubMedGoogle Scholar
- Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE: Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood. 2003, 102: 2236-2239. 10.1182/blood-2002-12-3899.View ArticlePubMedGoogle Scholar
- Withey JM, Marley SB, Kaeda J, Harvey AJ, Crompton MR, Gordon MY: Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Br J Haematol. 2005, 129: 377-380. 10.1111/j.1365-2141.2005.05468.x.View ArticlePubMedGoogle Scholar
- Rumpold H, Wolf AM, Gruenewald K, Gastl G, Gunsilius E, Wolf D: RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol. 2005, 33: 767-775. 10.1016/j.exphem.2005.03.014.View ArticlePubMedGoogle Scholar
- Devi RS: siRNA-based approaches in cancer therapy. Cancer Gene Ther. 2006, 13: 819-829. 10.1038/sj.cgt.7700931.View ArticlePubMedGoogle Scholar
- Whitehead KA, Langer R, Anderson DG: Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug Discov. 2009, 8: 129-138. 10.1038/nrd2742.View ArticlePubMedGoogle Scholar
- Cioca DP, Aoki Y, Kijosawa K: RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther. 2003, 10: 125-133. 10.1038/sj.cgt.7700544.View ArticlePubMedGoogle Scholar
- Zheng H, Chen Y, Chen S, Niu Y, Yang L, Li B, Lu Y, Geng S, Du X, Li Y: Expression and distribution of the PPP2R5C gene in leukemia. J Hematol Oncol. 2011, 4: 21-10.1186/1756-8722-4-21.PubMed CentralView ArticlePubMedGoogle Scholar
- Muneer S, Ramalingam V, Wyatt R, Schultz RA, Minna JD, Kamibayashi C: Genomic organization and mapping of the gene encoding the PP2A B56gamma regulatory subunit. Genomics. 2002, 79: 344-348. 10.1006/geno.2002.6721.View ArticlePubMedGoogle Scholar
- Lee TY, Lai TY, Lin SC, Wu CW, Ni IF, Yang YS, Hung LY, Law BK, Chiang CW: The B56gamma3 regulatory subunit of protein phosphatase 2A (PP2A) regulates S phase-specific nuclear accumulation of PP2A and the G1 to S transition. J Biol Chem. 2010, 285: 21567-21580. 10.1074/jbc.M109.094953.PubMed CentralView ArticlePubMedGoogle Scholar
- Shouse GP, Cai X, Liu X: Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol. 2008, 28: 448-456. 10.1128/MCB.00983-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Shouse GP, Nobumori Y, Liu X: A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A. Oncogene. 2010, 29: 3933-3941. 10.1038/onc.2010.161.PubMed CentralView ArticlePubMedGoogle Scholar
- Qiu L, Wang XD, Yu BH, Ge F, Wang XL, Chen LJ, Han BH, Zhan ZM, Zhang BL, Ma J: [Effect of a novel tyrosine kinase inhibitor HHGV678 on growth inhibition of Bcr-Abl wild type and IM-resistant cell lines in vitro]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008, 16: 1039-1043.PubMedGoogle Scholar
- Chen Y, Liu S, Shen Q, Zha X, Zheng H, Yang L, Chen S, Wu X, Li B, Li Y: Differential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells. DNA Cell Biol. 2013, 10.1089/dna.2013.2138. Aug 13. [Epub ahead of print]Google Scholar
- Huang X, Chen S, Shen Q, Chen S, Yang L, Grabarczyk P, Przybylski GK, Schmidt CA, Li Y: Down regulation of BCL11B expression inhibits proliferation and induces apoptosis in malignant T cells by BCL11B-935-siRNA. Hematology. 2011, 6: 236-242.View ArticleGoogle Scholar
- Huang X, Shen Q, Chen S, Chen S, Yang L, Weng J, Du X, Grabarczyk P, Przybylski GK, Schmidt CA, Li Y: Gene expression profiles in BCL11B-siRNA treated malignant T cells. J Hematol Oncol. 2011, 4: 23-10.1186/1756-8722-4-23.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen S, Huang X, Chen SH, Yang L, Shen Q, Zheng H, Li B, Grabarczyk P, Przybylski GK, Schmidt CA, Li Y: The role of BCL11B in regulating the proliferation of human naïve T cells. Hum Immunol. 2012, 73: 456-464. 10.1016/j.humimm.2012.02.018.View ArticlePubMedGoogle Scholar
- Zha X, Chen S, Yang L, Shi L, Li B, Wu X, Lu Y, Li Y: Up-regulated TCRζ enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol. 2012, 31: 1628-1635. 10.1089/dna.2012.1798.PubMed CentralView ArticlePubMedGoogle Scholar
- Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR: Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol. 2011, 4: 16-10.1186/1756-8722-4-16.PubMed CentralView ArticlePubMedGoogle Scholar
- Koldehoff M, Elmaagacli AH: Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia. Methods Mol Biol. 2009, 487: 451-466.PubMedGoogle Scholar
- Xia Y, Fang H, Zhang J, Du Y: Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide. Exp Biol Med (Maywood). 2013, [Epub ahead of print]Google Scholar
- Perrotti D, Neviani P: Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013, 14: e229-e238. 10.1016/S1470-2045(12)70558-2.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.